TET1 and fragile X syndrome: Similarly, TALE-TET1 and dCas9-TET1 fusions were employed as a way to treat diabetes via induction of β cell replication (59), to reactivate the TSG BRCA1 and inhibition of cell proliferation (60), to facilitate reprogramming of fibroblasts into myoblasts (61), and to potentially target diseases caused by dysregulated gene expression, such as Fragile X syndrome (62) (Figures 2B-IV, 3A-I).